Repligen reported fourth-quarter revenue of $168 million and full-year revenue of $634 million for 2024, with orders growing ahead of sales in the final quarter. The company provided 2025 guidance of 8% to 12% reported revenue growth and 10% to 14% growth excluding COVID-related revenue.

CEO Olivier Loeillot highlighted strong order momentum, particularly in the CDMO and capital equipment markets, which saw sequential revenue increases of approximately 20% and 30%, respectively. Repligen also closed its acquisition of Tantti Laboratory Inc., expanding its chromatography capabilities, and launched AVIPure® dsRNA resin, a novel solution for mRNA-based therapeutics.

Financially, adjusted gross profit for the fourth quarter was $85 million, down slightly from $87 million in 2023, while full-year adjusted gross profit increased to $320 million from $310 million. GAAP net loss for Q4 was $34 million compared to $16 million the previous year, impacted by $45 million in restructuring and inventory charges. Adjusted net income for Q4 was $25 million, down from $27 million, while full-year adjusted net income was $89 million compared to $93 million.

Margins were affected by restructuring costs, with GAAP gross margin at 23.2% for Q4 compared to 47.1% in 2023, though adjusted gross margin remained strong at 50.7%. Cash and cash equivalents stood at $757 million at year-end, reflecting stable liquidity. The company remains optimistic about bioprocessing market growth and expects continued momentum in 2025.